Next Generation Dx Summit features COVID-19 updates across four conferences: Enabling Point-of-Care Diagnostics, Point-of-Care Technologies, Advanced Diagnostics for Infectious Disease, and Diagnostics Reimbursement. Can't decide on a single program? We encourage program-hopping at the Next Generation Dx Summit to help attendees maximize their on-site experience.

CONFERENCE PROGRAMS:

Enabling Point-of-Care Diagnostics

August 25-26, 2020
View Program

Presentations:

Geospatial “Hot Spots” Need Rapid Point-of-Care Diagnostics to Stop Highly Infectious Threats and Antimicrobial Resistance
Gerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR); Emeritus Professor, School of Medicine, University of California, Davis

Rapid Development of Diagnostic Tests for New Threats: 2019 Novel Coronavirus Pneumonia (COVID-19) and Other Pathogens
Timothy Minogue, Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases

Point-of-Care Molecular Diagnostics for Disease Outbreak Settings: The Path to the Future
Rachel Spurbeck, PhD, Principal Research Scientist, Health Outcomes and Biotechnology Solutions, Battelle Memorial Institute

Point-of-Care Technologies

August 26-27, 2020
View Program

Presentations:

The Next Generation of Continuous Diagnostic Sensors: A Case Study on the Breakthroughs for Sweat Biosensing
Jason Heikenfeld, PhD, Vice President, Operations, Office of Innovation; Professor and Director, Novel Device Laboratory, University of Cincinnati

Engineering Biology for Diagnostic Solutions
William Blake, PhD, CTO, Sherlock Bioscience

Advanced Diagnostics for Infectious Disease

August 26-27, 2020
View Program

Presentations by:

DOD’s Pursuit of Pre-Symptomatic Non-Invasive Diagnostics
Edward Argenta, Science & Technology Manager, Biological & Chemical Technologies, Defense Threat Reduction Agency

The Biofire Pneumonia Panel: Does It Relate to Microbiological and Clinical Variables?
Kenneth Rand, MD, Medical Director, Clinical Microbiology Laboratory; Professor, Pathology and Medicine, University of Florida

The Challenges in Testing for COVID-19 and How do we Learn for the Next Pandemic
PANEL MODERATOR: Nathan Ledeboer, PhD, Professor and Vice Chair, Pathology and Medical Director, Medical College of Wisconsin

• Supply shortages, what can labs and the government do to be better prepared in an era of just in time shipping
• Regulatory changes, what changes are needed to ensure testing is not limited for the next pandemic?
• Some foundations such as Gates and Rockefeller are considering developing surveillance networks
• As we increasingly move to FDA cleared products, are we losing the ability to develop our own tests?
• What is the role of NGS-based assays in mass surveillance
• How do we solve the extraction challenge?
• Test performance was a major issue in COVID-19, what can we learn?

PANELISTS:
Norman Moore, PhD, Director, Scientific Affairs, Abbott
Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children’s Hospital Los Angeles; Associate Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California
Matthew Binnicker, PhD, Consultant, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology; Vice Chair of Supply Chain Management, Department of Laboratory Medicine and Pathology; Vice Chair of Practice, Department of Laboratory Medicine/Pathology, Mayo Clinic
Emily Crawford, PhD, Scientist II, Infectious Disease Initiative, Chan Zuckerberg Biohu

Coverage and Reimbursement for Advanced Diagnostics

August 25-26, 2020
View Program

Presentations:

Coding for The Frontlines: Establishing CPT® Codes for Novel Coronavirus (SARS-CoV-2) Tests
Zach Hochstetler, Director, CPT Editorial and Regulatory Services, American Medical Association, AMA

PANEL DISCUSSION: Hot Button Issues in Dx Reimbursement

Moderators:
Danielle Scelfo, Senior Director, Health Policy and Reimbursement, Hologic, Inc.
Ester Stein, MBA, Director, Corporate Reimbursement, Government Affairs, Abbott Laboratories
Panelists:
Jim Almas, MD, Vice President and National Medical Director, Clinical Effectiveness, LabCorp
Marc Hartstein, Principal, Health Policy Alternatives
Julie Khani, President, American Clinical Laboratory Association

REGISTER